Article Details

Zenas BioPharma Secures Up to $300 Million Synthetic Royalty Financing from Royalty Pharma

Retrieved on: 2025-09-22 07:54:41

Tags for this article:

Click the tags to see associated articles and topics

Zenas BioPharma Secures Up to $300 Million Synthetic Royalty Financing from Royalty Pharma. View article details on hiswai:

Excerpt

Ropes & Gray has advised Zenas BioPharma on the transaction, and Goodwin Procter and Maiwald GmbH have advised Royalty Pharma.Zenas BioPharma has ...

Article found on: globallegalchronicle.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up
Book a Demo